Discover how HSK31858 could transform bronchiectasis treatment by reducing flare-ups - read more about the latest trial ...

Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis, published ...

19 In the phase 2 WILLOW trial involving adults with bronchiectasis, treatment with a 10-mg or 25-mg dose of brensocatib, administered once daily for 24 weeks, prolonged the time to the first ...

NEJM Publishes New Global Clinical Trial Findings Showing Potential Power of Investigational Medication to Improve ...

A new phase 3 trial shows that DPP-1 inhibition with brensocatib reduces exacerbations and slows lung function decline in ...

Researchers have discovered in a new study that treating airway inflammation with the experimental drug brensocatib lowers ...

Treatment with brensocatib also increased time to the first exacerbation and the proportion of patients remaining ...

Panelists discuss how bacterial infections, environmental triggers, and microbiome imbalances cause bronchiectasis ...

Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis, chronic rhinosinusitis ...

Incorporated announced that positive results from the pivotal phase 3 ASPEN study of brensocatib in patients with non-cystic ...

Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis, published this April in the New England Journal of Medicine, demonstrated benefits ...

It may soon become the first-ever FDA-approved treatment for bronchiectasis. Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis ...